Gelex

Commission Implementing Regulation (EU) No 140/2012 of 17 February 2012 concerning the authorisation of monensin sodium as a feed additive for chickens reared for laying (holder of authorisation Huvepharma NV Belgium) (Text with EEA relevance)

In forceVersion 2012-02-17from 2012-03-09
Grade B

mapped from publisher markup. A grade says how a document's structure was obtained, not how reliable the law is.

Ask Gelex about this law

Address https://gelex.eu/eli/EU/regulation/2012/140@2012-02-17/en

Contents
  1. Preamble
    1. Article 1
    2. Article 2
  3. ANNEX
  4. ANNEX 1.2.3.4.5.6.

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in animal nutrition, and in particular Article 9(2) thereof,

Whereas:

(1) Regulation (EC) No 1831/2003 provides for the authorisation of additives for use in animal nutrition and for the grounds and procedures for granting such authorisation.

(2) In accordance with Article 7 of Regulation (EC) No 1831/2003, an application was submitted for the authorisation of monensin sodium. That application was accompanied by the particulars and documents required under Article 7(3) of Regulation (EC) No 1831/2003.

(3) The application concerns the authorisation of monensin sodium as a feed additive for chickens reared for laying, to be classified in the additive category coccidiostats and histomonostats.

(4) The use of monensin sodium was authorised for 10 years as a feed additive for use in chickens for fattening and turkeys up to 16 weeks by Commission Regulation (EC) No 109/2007.

(5) The European Food Safety Authority (the Authority) concluded in its opinion of 15 November 2011 that, under the proposed conditions of use, monensin sodium does not have an adverse effect on human health, animal health or the environment, and that its use is efficacious in controlling eimeria infections. It also verified the report on the method of analysis of the feed additive in feed submitted by the Reference Laboratory set up by Regulation (EC) No 1831/2003.

(6) The assessment of monensin sodium shows that the conditions for authorisation, as provided for in Article 5 of Regulation (EC) No 1831/2003, are satisfied. Accordingly, the use of this preparation should be authorised as specified in the Annex to this Regulation.

(7) The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on the Food Chain and Animal Health,

HAS ADOPTED THIS REGULATION:

Article 1

The preparation specified in the Annex, belonging to the additive category coccidiostats and histomonostats, is authorised as an additive in animal nutrition, subject to the conditions laid down in that Annex.

Article 2

This Regulation shall enter into force on the 20th day following its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States. Done at Brussels, 17 February 2012. For the Commission The President José Manuel Barroso

ANNEX

ANNEX 1.2.3.4.5.6.

Identification number of the additive Name of the holder of authorisation Additive (Trade name) Composition, chemical formula, description, analytical method Species or category of animal Maximum age Minimum content Maximum content Other provisions End of period of authorisation Provisional maximum residue limits (MRLs) in the relevant foodstuffs of animal origin mg of active substance/kg of complete feedingstuff with a moisture content of 12 % Coccidiostats and histomonostats 51701 Huvepharma NV Belgium Monensin sodium (Coxidin) Chickens reared for laying 16 weeks 100 125 Use prohibited at least 1 day before slaughter. The additive shall be incorporated in compound feedingstuffs in the form of a premixture. Monensin sodium shall not be mixed with other coccidiostats. Indicate in the instructions for use: Dangerous for equines. This feedingstuff contains an ionophore: avoid simultaneous administration with tiamulin and monitor for possible adverse reactions when used concurrently with other medicinal substances. Wear suitable protective clothing, gloves and eye/face protection. In case of insufficient ventilation in the premises, wear suitable respiratory equipment. A post-market monitoring programme on the resistance to Eimeria spp. shall be planned and executed by the holder of authorisation. 9 March 2022 25 μg monensin sodium/kg of wet skin + fat 8 μg monensin sodium/kg of wet liver, wet kidney and wet muscle

Additive composition

Monensin sodium technical substance equivalent to monensin activity: 25 %

Perlite: 15 %–20 %

Calcium carbonate q.s.100 %

Active substance C36H61O11Na Sodium salt of polyether monocarboxylic acid produced by Streptomyces cinnamonensis 28682, LMG S-19095 in powder form. Factor composition

Monensin A: not less than 90 %

Monensin A + B: not less than 95 %

Monensin C: 0,2-0,3 %

Analytical method Method for determination of the active substance: high performance liquid chromatography (HPLC) with post-column derivatisation and UV-VIS (EN ISO standard method 14183:2008)

Versions

  1. 2012-02-17

Cited by